Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2023-10-06 Share Issue/Capital Cha…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of a specific date (September 30, 2023). This content directly relates to changes in share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the total number of shares and voting rights, SHA is the most precise fit, as it covers capital structure changes, which this monthly update reflects.
2023-10-06 French
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Regulatory Filings Classification · 1% confidence The document explicitly states it provides 'Monthly information relative to the total number of voting rights and shares composing the share capital' and references French regulatory articles (L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation). This content—a monthly update on the total share capital and voting rights—is a specific regulatory disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Investor Presentation (IP). It most closely aligns with a specific regulatory disclosure concerning share structure and voting rights, which often falls under general regulatory announcements or specific share/capital change notifications. Given the options, this is a specific disclosure about the composition of the share capital and voting rights, which is a form of capital/share information. However, since it is a recurring, mandatory monthly disclosure about the total number of shares and voting rights, it is a specific regulatory filing. It is not a Director's Dealing (DIRS), a Major Shareholding Notification (MRQ, which tracks ownership thresholds), or a general Share Issue (SHA, which announces a new issuance). Since it is a mandatory, recurring regulatory disclosure that doesn't fit the other specific categories perfectly, it is best classified as a Regulatory Filing (RNS) or potentially a Share Issue/Capital Change (SHA) if the focus was purely on the denominator. Given the focus on 'voting rights' and 'share capital' as a monthly update, RNS is the most appropriate fallback for a specific, recurring regulatory disclosure not covered elsewhere. However, looking closely at the definitions, it is a notification about the capital structure, which is related to 'SHA' (Share Issue/Capital Change), but SHA usually implies an action. Since this is a mandatory disclosure of the current state of voting rights, RNS (General Regulatory Filings) is the safest classification for this specific type of monthly regulatory report.
2023-10-06 English
Ipsen fait le point sur la procédure réglementaire de la toxine QM-1114
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen dated October 3, 2023, detailing regulatory and legal updates concerning a product (QM-1114) developed with a partner (Galderma). Specifically, it mentions receiving a Complete Response Letter (CRL) from the FDA and the final decision from an international arbitration court (ICC) regarding regulatory submission strategy and intellectual property rights. This content directly relates to significant legal proceedings, regulatory setbacks, and partnership disputes. This strongly aligns with the definition of a Legal Proceedings Report (LTR), which covers significant lawsuits, regulatory actions, or legal matters involving the company. It is not a full financial report (10-K or IR), an earnings release (ER), or a general announcement of a report (RPA/RNS), as it provides substantive details about the legal/regulatory events themselves.
2023-10-03 French
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2023
Director's Dealing Classification · 1% confidence The document consists of detailed tables reporting transactions in financial instruments, specifically showing the 'Name of issuer' (IPSEN), 'Day of transaction', 'Aggregated daily volume (in number of shares)', and 'Daily weighted average price'. The presence of columns like 'Purpose of buy back' and the nature of the data (individual trades by an investment service provider like Exane SA) strongly indicates a report detailing personal share transactions by directors or executives, or in this context, transactions that must be disclosed due to insider status or significant holdings changes. The most fitting category for reporting personal share transactions by directors/executives is 'Director's Dealing' (DIRS). Although the document structure is highly specific (likely a regulatory filing format for insider transactions), DIRS covers this activity.
2023-10-03 English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2023
Director's Dealing Classification · 1% confidence The document text consists of detailed tables showing transactions involving the issuer 'IPSEN' and a counterparty 'Exane SA' (or similar entities like 'BNP PARIBAS EXANE'). The tables list transaction dates ('Jour de la transaction', 'Jour/heure de la transaction'), volume, price, and instrument identifiers. The presence of 'Quantité achetée' (Quantity bought) and the context of daily transaction reporting strongly indicate insider trading or director/executive share transactions. This aligns directly with the definition of 'Director's Dealing' (Code: DIRS). The document is a detailed report of transactions, not just an announcement of a report (RPA/RNS), and its length (42k chars) suggests it is the primary data filing.
2023-10-03 English
Ipsen updates on QM-1114 regulatory process
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen dated October 3, 2023, providing an update on the regulatory process for its product QM-1114, specifically mentioning a Complete Response Letter (CRL) from the FDA and the outcome of an ICC arbitration ruling regarding regulatory strategy assignment. This content relates to ongoing legal/regulatory matters and business developments concerning a specific product. It is not a comprehensive annual report (10-K), a quarterly report (IR), an earnings release (ER), or a formal shareholder vote result (DVA). Since it details the outcome of an arbitration and regulatory feedback concerning a product's submission strategy, it falls under the category of significant legal/regulatory updates or general corporate news. Given the specific focus on legal proceedings (arbitration) and regulatory feedback (FDA CRL), it aligns best with 'Legal Proceedings Report' (LTR) or potentially 'Regulatory Filings' (RNS) if LTR is too narrow. However, the core of the announcement revolves around the resolution of a dispute and regulatory setbacks, making LTR a strong candidate, though it's also a general corporate update. Since it details the final decision of an arbitration tribunal and regulatory feedback, it is a specific legal/regulatory event update. Given the options, 'LTR' (Legal Proceedings Report) covers the arbitration aspect well, but 'RNS' (Regulatory Filings) is often used for non-standard, material corporate announcements that don't fit the primary financial reports. Considering the document is a direct announcement of material legal/regulatory events (arbitration outcome and FDA CRL), and it is not a standard financial report, 'RNS' serves as the most appropriate general category for material, non-financial-statement regulatory news, although 'LTR' is also plausible due to the arbitration focus. I will select RNS as the best fit for a material, non-standard regulatory/legal update press release.
2023-10-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.